{"id":27759,"date":"2025-04-08T04:05:00","date_gmt":"2025-04-07T20:05:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=27759"},"modified":"2025-04-08T05:27:45","modified_gmt":"2025-04-07T21:27:45","slug":"lancet-global-health%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a2023%e5%b9%b4%e5%8d%97%e5%8d%8a%e7%90%83%e6%b5%81%e6%84%9f%e7%96%ab%e8%8b%97%e9%92%88%e5%af%b9%e9%87%8d%e7%97%87%e6%b5%81%e6%84%9f","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=27759","title":{"rendered":"[Lancet Global Health\u53d1\u8868\u8bba\u6587]\uff1a2023\u5e74\u5357\u534a\u7403\u6d41\u611f\u75ab\u82d7\u9488\u5bf9\u91cd\u75c7\u6d41\u611f\u76f8\u5173\u75be\u75c5\u7684\u6548\u679c"},"content":{"rendered":"\n

Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design<\/h1>\n\n\n\n

Radhika\u00a0Gharpure,\u00a0Annette K\u00a0Regan,\u00a0Francisco\u00a0Nogareda, et al<\/h3>\n\n\n\n

Lancet Global Health 2025; 13: e203-e211<\/h3>\n\n\n\n

https:\/\/doi.org\/10.1016\/S2214-109X(24)00473-X<\/h3>\n\n\n\n

Summary<\/h2>\n\n\n\n

Background<\/h3>\n\n\n\n

Annual estimates of seasonal influenza vaccine effectiveness can guide global risk communication and vaccination strategies to mitigate influenza-associated illness. We aimed to evaluate vaccine effectiveness in countries using the 2023 southern hemisphere influenza vaccine formulation.<\/p>\n\n\n\n

Methods<\/h3>\n\n\n\n

We evaluated end-of-season influenza vaccine effectiveness across eight countries (Argentina, Australia, Brazil, Chile, New Zealand, Paraguay, Thailand, and Uruguay) that used the 2023 southern hemisphere vaccine formulation, with use of a test-negative design. All patients who attended participating hospitals with severe acute respiratory illness were tested by RT-PCR for influenza. We calculated country-specific, network-specific, and pooled vaccine effectiveness against hospitalisation. For countries with sufficient data, we also calculated vaccine effectiveness against intensive care unit (ICU) admission by comparing the odds of vaccination among test-positive cases to that among test-negative controls. We evaluated vaccine effectiveness for groups prioritised for vaccination (young children aged 1\u20134 years, people aged 5\u201364 years with underlying health conditions, and older adults aged \u226565 years).<\/p>\n\n\n\n

Findings<\/h3>\n\n\n\n

From March 5 to Nov 27, 2023, 31\u2008368 individuals were admitted to hospital with severe acute respiratory infection in the eight included countries. Of these, 12\u2008609 individuals admitted to hospital (6452 [51\u00b72%] female and 6157 [48\u00b78%] male) who met inclusion criteria and had complete data were included in the analysis, including 4388 test-positive cases and 8221 test-negative controls. Pooled vaccine effectiveness against hospitalisation with any influenza virus was 51\u00b79% (95% CI 37\u00b72\u201366\u00b77), with substantial heterogeneity across countries (I<\/em>2<\/sup>\u00a074%). Vaccine effectiveness against ICU admission from any influenza virus was 67\u00b77% (44\u00b75\u201381\u00b72) in Chile and 69\u00b77% (45\u00b73\u201383\u00b73) in Australia. Vaccine effectiveness estimates against hospitalisation were highest for young children (70\u00b79% [47\u00b75\u201394\u00b74]) and lowest for older adults (47\u00b77% [24\u00b79\u201370\u00b75]).<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Interpretation<\/h3>\n\n\n\n

Across eight countries, 2023 southern hemisphere vaccines were effective in reducing hospitalisations from influenza illness. Use of common protocols can facilitate data pooling to provide a comprehensive evaluation of vaccine effectiveness across settings.<\/p>\n\n\n\n

Funding<\/h3>\n\n\n\n

US Centers for Disease Control and Prevention cooperative agreements to the Pan American Health Organization and the Thailand Ministry of Public Health; the Australian Government Department of Health and Aged Care; and the New Zealand Ministry of Health.<\/p>\n","protected":false},"excerpt":{"rendered":"

Effectiveness of 2023 southern hemisphere influenza vac […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27759"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27759"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27759\/revisions"}],"predecessor-version":[{"id":27760,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/27759\/revisions\/27760"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}